Autor: |
Tomonori Murayama, Yuji Ito, Kenji Narita, Tetsuro Ishida, Shiro Hinotsu, Masahiko Fujita |
Jazyk: |
angličtina |
Rok vydání: |
2024 |
Předmět: |
|
Zdroj: |
PCN Reports, Vol 3, Iss 1, Pp n/a-n/a (2024) |
Druh dokumentu: |
article |
ISSN: |
2769-2558 |
DOI: |
10.1002/pcn5.165 |
Popis: |
Abstract Aim Chronic insomnia disorder is common and associated with reduced quality of life. Benzodiazepine hypnotics are commonly prescribed for insomnia, but have potential side effects such as concentration impairment, somnolence, and dependence. Lemborexant (LEM) is an orexin receptor antagonist considered to have fewer side effects than benzodiazepine hypnotics. This study evaluated the effect of LEM on sleep in detail and examined whether benzodiazepine hypnotics can be gradually tapered by adding LEM. Methods We retrospectively examined the effectiveness of LEM in 28 outpatients with insomnia. Insomnia symptoms were assessed using the Athens Insomnia Scale (AIS) before and after LEM administration. We also attempted to taper benzodiazepine hypnotics and assessed benzodiazepine dose using diazepam equivalents for some patients taking benzodiazepine hypnotics. Wilcoxon's signed‐rank test was used for statistical analysis. Results The mean AIS score was significantly improved after LEM treatment (8.7 ± 5.2 vs. 3.8 ± 3.3; P |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|